Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00828477 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

A Phase 4 study of Intraocular Pressure, sponsored by Bp Consulting.

Completed
Registry status
Phase 4
Development phase
25
Enrollment target
1
Study location

NCT00828477 is a Phase 4 study of Intraocular Pressure that has completed, run by Bp Consulting. The registered enrollment target is 25 participants, below the 86-participant average among 9 other Intraocular Pressure trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00828477, a Phase 4 study of Intraocular Pressure, has completed, sponsored by Bp Consulting.

COMPLETED
Registry status
Phase 4
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac following SLT.

Conditions Studied

Interventions

  • DRUG Xibrom
  • DRUG Nevanac

Study Locations (1)

Michigan

  • Coburn-Kleinfeldt Eye Clinic - 3340 6 Mile Rd Livonia

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2009-01
Est. Completion 2009-06
Phase Phase 4

Sponsor

Bp Consulting

10 total trials

What the Registry Record Tells You About NCT00828477

The ClinicalTrials.gov registry entry for NCT00828477 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 9 other Intraocular Pressure trials with a reported enrollment target (71% lower). The listed sponsor is Bp Consulting, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Intraocular Pressure appearing as the primary indexed condition, and to 2 interventions - of which Xibrom is the first listed.

NCT00828477 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT00828477 about?

NCT00828477 is a clinical study titled "Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)". The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac following SLT.

What is the current status of trial NCT00828477?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2009-01. Estimated completion is 2009-06.

What conditions does trial NCT00828477 study?

This clinical trial studies the following conditions: Intraocular Pressure.

What interventions are being tested in trial NCT00828477?

The interventions under investigation include: Xibrom (DRUG), Nevanac (DRUG).

Who is sponsoring clinical trial NCT00828477?

This trial is sponsored by Bp Consulting, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00828477 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intraocular Pressure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.